Head-to-head evidence
Apomorphine sublingual film (Kynmobi) vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine sublingual film (Kynmobi)
Marketed by Sumitomo Pharma
NCT02469090 · Phase 3 · completed
The study randomized 109 patients to apomorphine sublingual film or matching placebo in a quadruple-blind design, with 54 patients receiving apomorphine and 55 receiving placebo. The primary clinical motor-function endpoint was met: the MDS-UPDRS Part III score improved more with apomorphine than placebo at Week 12 (p=0.0002).
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine sublingual film (Kynmobi)'s landscape · SER-252 (PEOZ-apomorphine)'s landscape